# Concerto Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/concerto-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.concertobio.com
- Total disclosed funding: $48M
- Latest round: Series A (Nov 2, 2022)
- Investors on record: 5

## About

Concerto Biosciences Inc. develops innovative microbial solutions for skincare, chronic disease management, and nutrition, utilizing advanced ecological datasets to enhance health and wellness applications.Founded in 2020 and headquartered in Boston, US, Concerto Biosciences specializes in microbial technology applications. The company has engaged in 5 deals to date, with its most recent funding round being a Series A of USD 23.00 mn on November 2, 2022, led by Safar Partners, and joined by Horizons Ventures and M Ventures. Cheri Ackerman serves as the CEO, with co-founders including Bernardo Cervantes, Jared Kehe, and Ravi Kumar.Concerto Biosciences specializes in leveraging microbial communities to develop innovative solutions for various applications, including skincare, chronic disease management, and nutrition. Their core offerings are driven by the kChip platform, which generates extensive ecological datasets that inform product development. The kAI model enhances these efforts by mapping microbial interactions and predicting their behavior, resulting in engineered microbial products that are applicable in real-world settings. Concerto’s products aim to address complex issues in consumer health and wellness, serving a diverse clientele that includes skincare manufacturers, healthcare providers, and nutritional product companies. The company focuses on markets in North America and Europe, targeting both consumer and professional segments to expand the reach and efficacy of their microbial-based solutions.Concerto Biosciences operates through a revenue model that emphasizes partnerships and direct client relationships, particularly with businesses in the healthcare and consumer goods sectors. The company engages in business-to-business transactions, collaborating with manufacturers and distributors to integrate its microbial solutions into their product lines. Clients benefit from the tailored application of Concerto's technology to enhance their offerings. Revenue generation occurs through subscription agreements, contractual partnerships, and potentially direct sales of proprietary products, structured to support ongoing collaborations, ensuring clients have continued access to Concerto's innovative microbial technologies as they evolve.In November 2022, Concerto Biosciences Inc. raised USD 23.00 mn in Series A funding, led by Safar Partners. The company plans to utilize this funding to accelerate the development of its first product and expand its product line while enhancing its platform. Concerto aims to introduce new products that address emerging needs in the skincare and healthcare sectors, targeting release by late 2023, and is exploring expansion into additional markets across Europe and Asia by 2024.

## Funding rounds

- Series A, Nov 2, 2022, $23M — Horizons Ventures, M Ventures, Safar Partners
- Series A, Jun 7, 2022, $8.5M — Alumni Ventures Group
- Series A, Mar 7, 2022, $16M — Alumni Ventures Group
- Seed, Dec 2, 2020, $0.1M — MassVentures, Safar Partners

## Investors

- MassVentures (https://capitalatlas.ai/funds/massventures) — Seed
- Safar Partners (https://capitalatlas.ai/funds/safar-partners) — Seed, Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Horizons Ventures — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A